NCT06830850 - A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 15, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

March 15, 2027

Conditions

Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG

HRS-5041 Single dose of HRS-5041 orally administered

HRS-5041 Oral dosage (Tablet) Oral dosage administration, 28 days per cycle.

Trial Locations (11)

ACTIVE_NOT_RECRUITING

GenesisCare North Shore (Oncology), Sydney

NOT_YET_RECRUITING

Sydney Adventist Hospital, Sydney

RECRUITING

Cancer Research SA, Adelaide

RECRUITING

Southern Oncology Clinical Research Unit, Adelaide

RECRUITING

Icon Cancer Centre South Brisbane, Brisbane

RECRUITING

John Flynn Private Hospital, Brisbane

NOT_YET_RECRUITING

Eastern Health (Box Hill Hospital), Melbourne

RECRUITING

Linear Clinical Research Ltd, Perth

RECRUITING

Macquarie University, Sydney

NOT_YET_RECRUITING

MUPharm Pty Limited trading as Macquarie University Hospital Pharmacy, Sydney

NOT_YET_RECRUITING

Illawarra Shoalhaven Local Health District (Wollongong Hospital), Wollongong

All Listed Sponsors

lead

Atridia Pty Ltd.

INDUSTRY